The distributions of patients in the high and low heterogeneity groups in the training and validation sets were compared in terms of patient age, menstrual status, hormone receptor (HR), human epidermal growth factor receptor 2 (HER2) status, Ki67 score, tumor T-stage, and N-stage, respectively (Table 1). The gene discussed is NR4A1; the disease is neoplasm.